Atom Investors’s Unity Biotechnology UBX Stock Holding History

Atom Investors’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,139	Closed	-$74K	–	576
2020 Q3	$74K	Buy	+2,139	New	+$135K	0.01%	486

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atom Investors's UBX Position: Q4 2020 in Review

Atom Investors sold out of Unity Biotechnology (UBX) in Q4 2020, closing a stake of 2,139 shares — an estimated $74K sold.

Atom Investors first reported a position in UBX in Q3 2020 and held it in 1 quarter. The position peaked at $74K in Q3 2020. 85 funds tracked by Wall St. Rank hold UBX as of Q4 2020.

Atom Investors reported no remaining Unity Biotechnology position as of Q4 2020 after selling out during the quarter.
Atom Investors sold 2,139 Unity Biotechnology shares in Q4 2020, an estimated $74K.
Atom Investors first reported a position in Unity Biotechnology in Q3 2020 and held it in 1 quarter.
Atom Investors's Unity Biotechnology position peaked at $74K in Q3 2020.
85 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2020.

Based on Atom Investors's 13F filing for Q4 2020, filed 16 Feb 2021.